Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Hepatology

Life with AIH: Monitoring and Long-Term Outlook

At a Glance

With consistent treatment, patients with autoimmune hepatitis (AIH) can achieve a normal life expectancy. Long-term management requires regular monitoring of liver enzymes and IgG levels, avoiding alcohol, and managing medication side effects to prevent silent disease flares.

Living with Autoimmune Hepatitis (AIH) is a marathon, not a sprint. While it is a chronic, life-long condition, the long-term outlook is generally very favorable for those who stay consistent with their treatment [1][2]. Most patients who achieve complete biochemical remission—meaning their liver enzymes (ALT/AST) and IgG levels return to normal—can expect a life expectancy similar to that of the general population [3][4].

Daily Life and Protecting Your Liver

When you are diagnosed with a liver condition, protecting the organ becomes a daily priority.

  • Alcohol: It is highly recommended to eliminate alcohol, as your liver is already under stress and alcohol causes direct liver inflammation.
  • Diet: There is no specific “AIH diet,” but a balanced, Mediterranean-style diet supports overall liver health and helps prevent fatty liver disease, which can complicate AIH.
  • Over-the-Counter Medications: Always check with your doctor before taking new supplements or medicines. Acetaminophen (Tylenol) is generally safe in limited doses, but you must ask your hepatologist for your specific safe limit. Avoid high doses of ibuprofen (Advil/Motrin), as it can interact with your immune medications and affect your kidneys.

Counteracting Medication Side Effects

Living on maintenance therapy requires proactive lifestyle adjustments:

  • Bone Health: Corticosteroids (like Prednisone) weaken bones. Ask your doctor if you need a DEXA scan to check your bone density. You should also ensure you are getting adequate Calcium and Vitamin D, either through diet or supplements.
  • Sun Protection: Because medications like Azathioprine increase the risk of skin cancer, daily sunscreen use and regular dermatologist checks are essential.

Monitoring Your Progress

Because AIH can be “silent” even when it is active, regular monitoring is essential to catch flares before they cause damage. Your care team will use several tools to track your health:

  • Blood Work: You will regularly test for ALT and AST (signs of liver cell damage) and IgG (a sign of immune system activity) [5][6].
  • Transient Elastography (FibroScan): This is a painless, non-invasive “ultrasound-like” test that measures liver stiffness. It helps doctors track whether scarring (fibrosis) is stable, worsening, or even improving in response to treatment [7][8].
  • Imaging: If you have developed cirrhosis, you will need an abdominal ultrasound every 6 months to screen for hepatocellular carcinoma (HCC), a type of liver cancer that can develop in scarred liver tissue [9][10].

Suggested Surveillance Schedule

While every patient is different, a typical long-term monitoring plan often looks like this:

Test Frequency (In Remission) Purpose
Liver Enzymes (ALT/AST) Every 3–6 months Detect early signs of a flare [11]
IgG Levels Every 6–12 months Monitor overall immune activity [6]
FibroScan Every 12–24 months Check for changes in liver scarring [7]
HCC Ultrasound Every 6 months Cancer screening (only if cirrhosis is present) [10]

Long-Term Risks and “Overlap”

Even with good control, your medical team will stay alert for two specific changes:

  1. Biliary Progression: About 20% of AIH patients may develop signs of bile duct disease over time, such as Primary Sclerosing Cholangitis (PSC) [12]. This risk is higher in people who also have inflammatory bowel disease (IBD) [12].
  2. Other Autoimmune Conditions: Because your immune system is prone to overactivity, it is common to develop “extrahepatic” (outside the liver) conditions, such as thyroid disease, celiac disease, or rheumatoid arthritis [13][14].

The Psychological Journey

Managing a chronic illness takes a toll that isn’t always visible in blood tests. The “watch and wait” nature of regular monitoring can cause anxiety. It is important to remember that a flare is not a failure; it is a common part of the disease that can be managed by adjusting your medications [15][11]. Many patients find that connecting with support groups or mental health professionals helps them manage the emotional aspects of living with an autoimmune condition.

Common questions in this guide

How often do I need to get my liver enzymes checked with AIH?
When your autoimmune hepatitis is in remission, you will typically need your ALT and AST liver enzymes checked every 3 to 6 months. This routine blood work helps your doctor catch early signs of a disease flare before it causes visible symptoms or liver damage.
Can I drink alcohol if I have autoimmune hepatitis?
It is highly recommended to eliminate alcohol entirely if you have autoimmune hepatitis. Alcohol causes direct inflammation and places unnecessary stress on a liver that is already vulnerable to damage from your immune system.
Why might I need a DEXA scan for AIH?
Corticosteroids like Prednisone, which are frequently used to treat AIH, can weaken your bones over time. A DEXA scan checks your bone density to ensure you are not developing osteoporosis and helps your doctor decide if you need bone-protecting treatments.
What is a FibroScan and why do I need one?
A FibroScan is a painless, non-invasive test similar to an ultrasound that measures the stiffness of your liver. It allows your care team to monitor liver scarring over time without needing to perform repeated liver biopsies.
Is it safe to take over-the-counter pain medicine like Tylenol?
Acetaminophen, the active ingredient in Tylenol, is generally safe in limited doses for people with AIH. However, you must ask your hepatologist to determine your specific safe dose limit based on your current liver health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current lab results, exactly how often should I have my ALT, AST, and IgG levels checked?
  2. 2.Given my steroid use, should I have a DEXA scan to check my bone density?
  3. 3.Do I have any signs of cirrhosis that would require me to start 6-month ultrasound screenings for liver cancer (HCC)?
  4. 4.Can we use a FibroScan to monitor my liver stiffness instead of doing another biopsy?
  5. 5.Are there specific over-the-counter medications, like Tylenol, that I should limit or avoid completely?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    [Treatment of autoimmune hepatitis-First-line, second-line and third-line treatment].

    Taubert R, Engel B

    Innere Medizin (Heidelberg, Germany) 2024; (65(4)):325-333 doi:10.1007/s00108-024-01679-2.

    PMID: 38456902
  2. 2

    Characteristics and Long-Term Outcome of 535 Patients with Autoimmune Hepatitis-The 20-Year Experience of a High-Volume Tertiary Center.

    Buechter M, Dorn D, Möhlendick B, et al.

    Journal of clinical medicine 2023; (12(13)) doi:10.3390/jcm12134192.

    PMID: 37445225
  3. 3

    Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis.

    Biewenga M, Verhelst X, Baven-Pronk M, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022; (20(8)):1776-1783.e4 doi:10.1016/j.cgh.2021.05.024.

    PMID: 34022454
  4. 4

    Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study.

    Plagiannakos CG, Hirschfield GM, Lytvyak E, et al.

    Journal of hepatology 2024; (81(2)):227-237 doi:10.1016/j.jhep.2024.03.021.

    PMID: 38527524
  5. 5

    Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country.

    Choi J, Choi GH, Lee D, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2019; (39(5)):985-994 doi:10.1111/liv.14082.

    PMID: 30821090
  6. 6

    Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis.

    Dalekos GN, Papatheodoridis GV, Koskinas J, et al.

    Annals of gastroenterology 2024; (37(6)):623-654 doi:10.20524/aog.2024.0924.

    PMID: 39568707
  7. 7

    Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.

    Hartl J, Ehlken H, Sebode M, et al.

    Journal of hepatology 2018; (68(4)):754-763 doi:10.1016/j.jhep.2017.11.020.

    PMID: 29180000
  8. 8

    Transient Elastography (FibroScan) Performs Better Than Non-Invasive Markers in Assessing Liver Fibrosis and Cirrhosis in Autoimmune Hepatitis Patients.

    Guo L, Zheng L, Hu L, et al.

    Medical science monitor : international medical journal of experimental and clinical research 2017; (23()):5106-5112 doi:10.12659/msm.907300.

    PMID: 29073121
  9. 9

    Hepatocellular Carcinoma in Patients With Liver Cirrhosis Secondary to Autoimmune Hepatitis: A Case Series and Literature Review.

    Perera Mesa H, Lugo L, Altshuler E

    Cureus 2022; (14(10)):e30698 doi:10.7759/cureus.30698.

    PMID: 36439579
  10. 10

    EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.

    Journal of hepatology 2025; (83(2)):453-501 doi:10.1016/j.jhep.2025.03.017.

    PMID: 40348684
  11. 11

    Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom.

    Dyson JK, Wong LL, Bigirumurame T, et al.

    Alimentary pharmacology & therapeutics 2018; (48(9)):951-960 doi:10.1111/apt.14968.

    PMID: 30226274
  12. 12

    Biliary disease progression in childhood onset autoimmune liver disease: A 30-year follow-up into adulthood.

    Warner S, Rajanayagam J, Russell E, et al.

    JHEP reports : innovation in hepatology 2024; (6(2)):100901 doi:10.1016/j.jhepr.2023.100901.

    PMID: 38235169
  13. 13

    Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes.

    Wong GW, Yeong T, Lawrence D, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2017; (37(3)):449-457 doi:10.1111/liv.13236.

    PMID: 27541063
  14. 14

    Clinical outcomes in patients with autoimmune hepatitis and primary biliary cholangitis overlap syndrome in the United States.

    Goyal RM, Bansal B, Ayyad M, et al.

    Clinics and research in hepatology and gastroenterology 2025; (49(6)):102598 doi:10.1016/j.clinre.2025.102598.

    PMID: 40294647
  15. 15

    Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)?

    Harrison L, Gleeson D

    Liver international : official journal of the International Association for the Study of the Liver 2019; (39(4)):610-620 doi:10.1111/liv.14051.

    PMID: 30667576

This page explains long-term monitoring and lifestyle management for autoimmune hepatitis for educational purposes. Always consult your hepatologist or care team before changing your diet, medications, or surveillance schedule.

Get notified when new evidence is published on Autoimmune hepatitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.